David Alan Preiss, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2022 | 3251 | 1.520 |
Why?
|
| Anticholesteremic Agents | 9 | 2020 | 970 | 1.310 |
Why?
|
| Diabetic Angiopathies | 5 | 2019 | 805 | 1.300 |
Why?
|
| Diabetes Mellitus | 13 | 2019 | 5891 | 1.170 |
Why?
|
| Cardiovascular Diseases | 25 | 2022 | 15652 | 1.060 |
Why?
|
| Hypolipidemic Agents | 3 | 2015 | 608 | 1.010 |
Why?
|
| Cholesterol, LDL | 7 | 2020 | 2393 | 0.880 |
Why?
|
| Hypercholesterolemia | 3 | 2017 | 1149 | 0.720 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2023 | 12240 | 0.710 |
Why?
|
| Hypertriglyceridemia | 2 | 2014 | 290 | 0.680 |
Why?
|
| Cholesterol | 3 | 2015 | 2898 | 0.670 |
Why?
|
| Blood Glucose | 10 | 2020 | 6424 | 0.640 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2019 | 111 | 0.590 |
Why?
|
| Cyclohexanes | 3 | 2015 | 151 | 0.570 |
Why?
|
| Body Weight | 3 | 2017 | 4622 | 0.550 |
Why?
|
| Motor Activity | 3 | 2015 | 2704 | 0.530 |
Why?
|
| Capnography | 1 | 2017 | 90 | 0.520 |
Why?
|
| Phenylalanine | 3 | 2015 | 367 | 0.520 |
Why?
|
| Pancreatitis | 2 | 2013 | 1087 | 0.510 |
Why?
|
| Hypoglycemic Agents | 7 | 2019 | 3110 | 0.500 |
Why?
|
| Glucose Intolerance | 3 | 2015 | 580 | 0.500 |
Why?
|
| Respiratory Rate | 1 | 2017 | 179 | 0.500 |
Why?
|
| Triglycerides | 3 | 2013 | 2441 | 0.490 |
Why?
|
| Clinical Chemistry Tests | 1 | 2015 | 59 | 0.480 |
Why?
|
| Niacin | 1 | 2015 | 116 | 0.470 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 969 | 0.460 |
Why?
|
| Tetrazoles | 3 | 2017 | 920 | 0.460 |
Why?
|
| Gangrene | 1 | 2014 | 92 | 0.450 |
Why?
|
| Fibric Acids | 1 | 2012 | 27 | 0.400 |
Why?
|
| Risk Reduction Behavior | 4 | 2020 | 1123 | 0.400 |
Why?
|
| Heart Failure | 11 | 2017 | 11840 | 0.400 |
Why?
|
| Valine | 1 | 2013 | 410 | 0.380 |
Why?
|
| Actigraphy | 2 | 2015 | 532 | 0.360 |
Why?
|
| Monitoring, Ambulatory | 1 | 2014 | 357 | 0.360 |
Why?
|
| Diabetic Neuropathies | 1 | 2014 | 408 | 0.350 |
Why?
|
| Lipoproteins | 2 | 2014 | 866 | 0.350 |
Why?
|
| Dyslipidemias | 2 | 2015 | 869 | 0.340 |
Why?
|
| Diabetes Complications | 2 | 2016 | 1316 | 0.340 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2015 | 394 | 0.340 |
Why?
|
| Monitoring, Physiologic | 3 | 2017 | 1792 | 0.340 |
Why?
|
| Antibodies, Monoclonal | 5 | 2017 | 9249 | 0.330 |
Why?
|
| Coronary Disease | 3 | 2020 | 5912 | 0.330 |
Why?
|
| Respiratory Muscles | 1 | 2009 | 144 | 0.310 |
Why?
|
| Spironolactone | 1 | 2012 | 415 | 0.300 |
Why?
|
| Respiration | 3 | 2017 | 1653 | 0.300 |
Why?
|
| Glucose Tolerance Test | 4 | 2016 | 1180 | 0.290 |
Why?
|
| Blood Pressure | 6 | 2023 | 8532 | 0.290 |
Why?
|
| Walking | 1 | 2014 | 1198 | 0.270 |
Why?
|
| Metformin | 2 | 2014 | 904 | 0.270 |
Why?
|
| Physical Endurance | 1 | 2009 | 368 | 0.270 |
Why?
|
| Risk Factors | 26 | 2020 | 74840 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 15 | 2019 | 10383 | 0.270 |
Why?
|
| Fatty Liver | 2 | 2010 | 807 | 0.250 |
Why?
|
| Multifactorial Inheritance | 1 | 2014 | 1425 | 0.250 |
Why?
|
| Humans | 77 | 2023 | 765968 | 0.250 |
Why?
|
| Oxygen | 1 | 2017 | 4241 | 0.240 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 878 | 0.240 |
Why?
|
| Troponin T | 3 | 2019 | 785 | 0.240 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 1299 | 0.240 |
Why?
|
| Cardiac Output, Low | 2 | 2015 | 192 | 0.230 |
Why?
|
| Troponin I | 2 | 2019 | 655 | 0.230 |
Why?
|
| Stroke | 3 | 2015 | 9747 | 0.220 |
Why?
|
| Anesthesia | 3 | 2021 | 1590 | 0.220 |
Why?
|
| Mass Screening | 3 | 2018 | 5446 | 0.210 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2023 | 110 | 0.200 |
Why?
|
| Research Design | 4 | 2016 | 6209 | 0.190 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 8041 | 0.190 |
Why?
|
| Exercise Test | 1 | 2009 | 2180 | 0.190 |
Why?
|
| Glucosides | 2 | 2023 | 531 | 0.180 |
Why?
|
| Anesthesiology | 2 | 2023 | 1135 | 0.170 |
Why?
|
| Respiration, Artificial | 3 | 2009 | 2709 | 0.160 |
Why?
|
| Esters | 1 | 2020 | 214 | 0.160 |
Why?
|
| Stroke Volume | 4 | 2017 | 5596 | 0.150 |
Why?
|
| Hyperlipidemias | 2 | 2015 | 770 | 0.150 |
Why?
|
| Equipment Design | 4 | 2019 | 3481 | 0.150 |
Why?
|
| Sulfhydryl Compounds | 1 | 2020 | 296 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 2686 | 0.150 |
Why?
|
| Laryngeal Masks | 1 | 2019 | 103 | 0.150 |
Why?
|
| Exercise | 3 | 2014 | 5937 | 0.150 |
Why?
|
| Male | 32 | 2020 | 363698 | 0.140 |
Why?
|
| Risk | 4 | 2014 | 9591 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7425 | 0.140 |
Why?
|
| Anesthesia Department, Hospital | 1 | 2017 | 69 | 0.140 |
Why?
|
| Amides | 1 | 2020 | 455 | 0.140 |
Why?
|
| Models, Statistical | 2 | 2009 | 5089 | 0.140 |
Why?
|
| Pharmacology, Clinical | 1 | 2016 | 23 | 0.140 |
Why?
|
| Risk Assessment | 8 | 2019 | 24282 | 0.130 |
Why?
|
| Myocardial Infarction | 3 | 2015 | 11499 | 0.130 |
Why?
|
| Electronic Health Records | 4 | 2017 | 4873 | 0.130 |
Why?
|
| Female | 32 | 2020 | 396112 | 0.130 |
Why?
|
| Double-Blind Method | 5 | 2023 | 12437 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 2310 | 0.130 |
Why?
|
| Middle Aged | 24 | 2020 | 223009 | 0.130 |
Why?
|
| Metabolomics | 2 | 2016 | 1668 | 0.130 |
Why?
|
| Body Mass Index | 6 | 2019 | 13039 | 0.130 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2016 | 89 | 0.130 |
Why?
|
| Muscular Diseases | 2 | 2017 | 550 | 0.120 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2015 | 84 | 0.120 |
Why?
|
| Thermodynamics | 1 | 2017 | 580 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 15398 | 0.120 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2015 | 172 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2011 | 3424 | 0.120 |
Why?
|
| Biphenyl Compounds | 2 | 2017 | 1019 | 0.120 |
Why?
|
| Incidence | 6 | 2020 | 21480 | 0.120 |
Why?
|
| Aortic Aneurysm | 1 | 2019 | 623 | 0.120 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2014 | 64 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 6309 | 0.110 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 1044 | 0.110 |
Why?
|
| Documentation | 1 | 2021 | 916 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 639 | 0.110 |
Why?
|
| Hyperkalemia | 1 | 2016 | 233 | 0.110 |
Why?
|
| Prediabetic State | 2 | 2020 | 548 | 0.110 |
Why?
|
| Enalapril | 1 | 2016 | 317 | 0.110 |
Why?
|
| Oximetry | 1 | 2017 | 459 | 0.110 |
Why?
|
| Video Recording | 1 | 2019 | 969 | 0.110 |
Why?
|
| Laryngoscopy | 1 | 2019 | 686 | 0.110 |
Why?
|
| Proteinuria | 1 | 2016 | 607 | 0.110 |
Why?
|
| Drug Dosage Calculations | 1 | 2013 | 116 | 0.110 |
Why?
|
| Aged | 20 | 2020 | 171117 | 0.100 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2013 | 187 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2016 | 1061 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2016 | 1514 | 0.100 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 12509 | 0.100 |
Why?
|
| Alanine Transaminase | 2 | 2011 | 607 | 0.100 |
Why?
|
| Disease Progression | 4 | 2016 | 13632 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 939 | 0.090 |
Why?
|
| Tunica Intima | 1 | 2013 | 455 | 0.090 |
Why?
|
| Age Distribution | 2 | 2015 | 2858 | 0.090 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2005 | 418 | 0.090 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 179 | 0.090 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 1303 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 790 | 0.090 |
Why?
|
| Insulin Resistance | 2 | 2014 | 3985 | 0.080 |
Why?
|
| American Heart Association | 1 | 2015 | 1047 | 0.080 |
Why?
|
| Ventricular Function, Left | 2 | 2016 | 3928 | 0.080 |
Why?
|
| Gallstones | 1 | 2012 | 285 | 0.080 |
Why?
|
| Waist Circumference | 1 | 2013 | 932 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2015 | 2263 | 0.080 |
Why?
|
| Cause of Death | 3 | 2015 | 3708 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1237 | 0.080 |
Why?
|
| Cohort Studies | 6 | 2020 | 41649 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2011 | 9649 | 0.080 |
Why?
|
| Canada | 1 | 2015 | 2119 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 10729 | 0.080 |
Why?
|
| Clofibric Acid | 1 | 2008 | 8 | 0.080 |
Why?
|
| Scotland | 2 | 2019 | 115 | 0.080 |
Why?
|
| Fasting | 1 | 2015 | 1606 | 0.080 |
Why?
|
| Prospective Studies | 8 | 2017 | 54802 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2015 | 1472 | 0.080 |
Why?
|
| Breath Tests | 1 | 2009 | 297 | 0.070 |
Why?
|
| Algorithms | 1 | 2008 | 14071 | 0.070 |
Why?
|
| Mortality | 2 | 2016 | 2904 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 3421 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 16047 | 0.070 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 1892 | 0.070 |
Why?
|
| Ventilators, Mechanical | 1 | 2009 | 291 | 0.070 |
Why?
|
| ROC Curve | 2 | 2016 | 3620 | 0.070 |
Why?
|
| Cardiovascular System | 1 | 2014 | 841 | 0.070 |
Why?
|
| Carbon Dioxide | 3 | 2005 | 1137 | 0.070 |
Why?
|
| Anesthesia, Closed-Circuit | 1 | 2005 | 14 | 0.060 |
Why?
|
| Treatment Outcome | 8 | 2019 | 65188 | 0.060 |
Why?
|
| Respiratory Dead Space | 1 | 2005 | 31 | 0.060 |
Why?
|
| Albuminuria | 1 | 2010 | 660 | 0.060 |
Why?
|
| Placental Circulation | 1 | 2005 | 37 | 0.060 |
Why?
|
| Fatigue | 1 | 2013 | 1549 | 0.060 |
Why?
|
| Hospitalization | 3 | 2017 | 10808 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 15880 | 0.060 |
Why?
|
| Comorbidity | 3 | 2016 | 10563 | 0.060 |
Why?
|
| Adult | 11 | 2022 | 223044 | 0.060 |
Why?
|
| Disease Management | 1 | 2015 | 2535 | 0.060 |
Why?
|
| Physicians | 1 | 2023 | 4588 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 3672 | 0.060 |
Why?
|
| Echocardiography | 1 | 2017 | 5045 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 2334 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2015 | 6322 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2014 | 2692 | 0.060 |
Why?
|
| Anesthesia, Inhalation | 1 | 2004 | 216 | 0.060 |
Why?
|
| Prognosis | 5 | 2019 | 29922 | 0.050 |
Why?
|
| Animals | 6 | 2019 | 168764 | 0.050 |
Why?
|
| Life Style | 1 | 2015 | 3926 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 2033 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1370 | 0.050 |
Why?
|
| Benzhydryl Compounds | 2 | 2023 | 939 | 0.050 |
Why?
|
| Hyperoxia | 1 | 2005 | 260 | 0.050 |
Why?
|
| Time Factors | 4 | 2019 | 40065 | 0.050 |
Why?
|
| Ultrasonography, Doppler | 1 | 2005 | 460 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2013 | 1984 | 0.050 |
Why?
|
| Young Adult | 3 | 2017 | 59889 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2011 | 1393 | 0.050 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2004 | 136 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2008 | 2910 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2023 | 5946 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2015 | 3956 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2022 | 6255 | 0.050 |
Why?
|
| Uterus | 1 | 2005 | 661 | 0.050 |
Why?
|
| Masks | 1 | 2004 | 209 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 39193 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2013 | 3047 | 0.040 |
Why?
|
| Smoking | 3 | 2015 | 9081 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 4058 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2021 | 81514 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 1870 | 0.040 |
Why?
|
| Goals | 1 | 2023 | 719 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2017 | 1736 | 0.040 |
Why?
|
| Hospital Departments | 1 | 2017 | 135 | 0.040 |
Why?
|
| Water | 1 | 2023 | 1417 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2005 | 1774 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2010 | 22223 | 0.030 |
Why?
|
| Survival Rate | 1 | 2011 | 12795 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 15842 | 0.030 |
Why?
|
| Reference Values | 2 | 2018 | 4908 | 0.030 |
Why?
|
| Adrenomedullin | 1 | 2016 | 85 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 20124 | 0.030 |
Why?
|
| Apolipoprotein B-100 | 1 | 2016 | 157 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 6544 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2016 | 348 | 0.030 |
Why?
|
| Cross Infection | 1 | 2004 | 1427 | 0.030 |
Why?
|
| Liver | 1 | 2010 | 7562 | 0.030 |
Why?
|
| Cystatin C | 1 | 2016 | 272 | 0.030 |
Why?
|
| Glycopeptides | 1 | 2016 | 224 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2022 | 1187 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 697 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2016 | 238 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2016 | 410 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2011 | 4736 | 0.030 |
Why?
|
| Finland | 1 | 2015 | 608 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2017 | 5125 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2009 | 9347 | 0.030 |
Why?
|
| Sex Factors | 2 | 2018 | 10603 | 0.030 |
Why?
|
| Age Factors | 3 | 2018 | 18380 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2004 | 3564 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2015 | 10070 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2019 | 788 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 429 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2016 | 1589 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2016 | 1134 | 0.020 |
Why?
|
| Workflow | 1 | 2016 | 862 | 0.020 |
Why?
|
| Anesthetics | 1 | 2016 | 525 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2010 | 140 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1441 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 687 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2016 | 2077 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 59489 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 5526 | 0.020 |
Why?
|
| Hypertension | 1 | 2009 | 8626 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 1811 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 2233 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 2194 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2009 | 14652 | 0.020 |
Why?
|
| Acute Coronary Syndrome | 1 | 2020 | 2184 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2023 | 4863 | 0.020 |
Why?
|
| Obesity | 1 | 2009 | 13076 | 0.020 |
Why?
|
| United States | 1 | 2015 | 72903 | 0.020 |
Why?
|
| Forecasting | 1 | 2015 | 2936 | 0.020 |
Why?
|
| Hypocapnia | 1 | 2005 | 38 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2005 | 19 | 0.020 |
Why?
|
| Health Status | 1 | 2019 | 4080 | 0.020 |
Why?
|
| Umbilical Arteries | 1 | 2005 | 78 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 6832 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6499 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2017 | 3832 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 2005 | 380 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2005 | 235 | 0.010 |
Why?
|
| Patient Selection | 1 | 2016 | 4255 | 0.010 |
Why?
|
| Hypercapnia | 1 | 2005 | 259 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 3850 | 0.010 |
Why?
|
| Middle Cerebral Artery | 1 | 2005 | 268 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3106 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 1731 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2005 | 389 | 0.010 |
Why?
|
| Tidal Volume | 1 | 2005 | 519 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12056 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2005 | 941 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2005 | 1381 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 26318 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 2005 | 717 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2014 | 3595 | 0.010 |
Why?
|
| Aerosols | 1 | 2004 | 633 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2016 | 3458 | 0.010 |
Why?
|
| Kidney | 1 | 2016 | 7066 | 0.010 |
Why?
|
| Lipids | 1 | 2011 | 3315 | 0.010 |
Why?
|
| Arteries | 1 | 2005 | 1118 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 2475 | 0.010 |
Why?
|
| Child | 1 | 2008 | 80564 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2844 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12807 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 14751 | 0.010 |
Why?
|
| Logistic Models | 1 | 2013 | 13266 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 18071 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2010 | 5993 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 30260 | 0.000 |
Why?
|